AndhraNews.net
Home » Business News » 2013 » July » July 23, 2013

Galapagos delivers novel osteoarthritis molecules in alliance with Servier


July 23, 2013 - Mechelen, Belgium

Galapagos NV (Euronext: GLPG) announcedtodaythe achievement of a late stage discovery milestone for small moleculesagainsta novel target in the osteoarthritis (OA) alliance with Servier. Thismilestonetriggered a payment to Galapagos of EUR3 million and will contributeto Grouprevenues in the first half of 2013.

"Galapagos already delivered multiple compounds against different OAtargetsinto late discovery and selected a preclinical candidate last year.Today'sachievement is consistent with our strategy to move multiple, novelmechanism-of-action programs toward the clinic, thereby increasing thechances of successin disease areas with high unmet medical needs," said Onno van de Stolpe,CEO ofGalapagos.

"Galapagos is delivering what we aimed for in our alliance to discover neworaltherapies in osteoarthritis. Servier is committed to developing medicineswhichactually address the causes of osteoarthritis, a debilitating illness forwhichno disease-modifying treatment is available," said Dr PatriciaBelissa-Mathiot, Director of Rheumatology Innovative Pole.

In July 2010, Servier and Galapagos announced their alliance to develop neworalmedicines for the treatment of osteoarthritis (OA). Galapagos isresponsiblefor the discovery and development of new candidate drugs against noveltargets,and Servier has an exclusive option to license these after thecompletion ofPhase 1 clinical trials. Galapagos is eligible to receive up to EUR290million insuccess-based milestones, plus royalties on commercial sales. Galapagosalsoretains exclusive US commercialization rights to all commercial compounds.

About Servier

Servier is a privately-run research based pharmaceutical company with a2012turnover of EUR3.9 billion. Servier reinvests 25% of its turnover inResearch &Development in cardiovascular, metabolic, neurological, psychiatric andbone andjoint diseases as well as oncology. Servier is established in 140countriesworldwide with over 20,000 employees. More info at: www.servier.com

About Galapagos

Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novelmodes-of-action, with a large pipeline of five clinical, sixpre-clinical, and 30 discovery small-molecule and antibody programsin cystic fibrosis, inflammation,antibiotics, metabolic disease, and other indications.GLPG0634 is an orally-available, selective inhibitor of JAK1 for thetreatmentof rheumatoid arthritis and potentially other inflammatory diseases,currentlyin Phase 2B studies in RA and about to enter Phase 2 studies inCrohn'sdisease. AbbVie and Galapagos signed a worldwide license agreementwherebyAbbVie will be responsible for further development and commercializationafterPhase 2B. Galapagos has another selective JAK1 inhibitor in Phase 2 inlupusand psoriasis, GSK2586184 (formerly GLPG0778, in-licensed byGlaxoSmithKline in2012). GLPG0187 is a novel integrin receptor antagonist currently in aPhase1B patient study in metastasis. GLPG0974 is the first inhibitor of FFA2to beevaluated clinically for the treatment of IBD; this program is currentlyin aProof of Concept Phase 2 study. GLPG1205 is a first-in-class moleculethattargets inflammatory disorders and is currently in a First-in-HumanPhase 1study.

The Galapagos Group, including fee-for-service companies BioFocus,Argenta andFidelta, has 800 employees and operates facilities in five countries,withglobal headquarters in Mechelen, Belgium. Further information at:www.glpg.com

Galapagos forward-looking statements

This release may contain forward-looking statements, including, withoutlimitation, statements containing the words "believes," "anticipates,""expects," "intends," "plans," "seeks," "estimates," "may," "will,""could,""stands to," and "continues," as well as similar expressions. Suchforward-looking statements may involve known and unknown risks,uncertainties and otherfactors which might cause the actual results, financial condition,performanceor achievements of Galapagos, or industry results, to be materiallydifferentfrom any historic or future results, financial conditions, performance orachievements expressed or implied by such forward-looking statements. Giventhese uncertainties, the reader is advised not to place any undue relianceonsuch forward-looking statements. These forward-looking statements speakonly asof the date of publication of this document. Galapagos expressly disclaimsanyobligation to update any such forward-looking statements in this documenttoreflect any change in its expectations with regard thereto or any change inevents, conditions or circumstances on which any such statement is based,unlessrequired by law or regulation.

Galapagos delivers novel osteoarthritis molecules in alliance:http://hugin.info/133350/R/1717970/571388.pdf

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Galapagos NV via Thomson Reuters ONE

[HUG#1717970]

CONTACTS

Servier
Servier Communication Department
Tel: +33 1 55 72 60 37
Email Contact

Galapagos NV
Onno van de Stolpe
Chief Executive Officer
Tel: +31 6 2909 8028
Email Contact

MarketWire

Comment on this story

Share